Top

Published in:

01-04-2016 | Original Article

Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer

Authors: Shiying Zhang, Jianye Li, Gaobiao Zhou, Dawei Mu, Jingmin Yan, Jizhang Xing, Zhiyong Yao, Haibo Sheng, Di Li, Chao Lv, Bin Sun, Quan Hong, Heqing Guo

Published in: Tumor Biology | Issue 4/2016

Abstract

There is increasing evidence suggesting that establishment of sister chromatid cohesion N-acetyltransferase 1 (ESCO1) was involved in tumorigenesis. However, its role in bladder cancer remains unclear. In this study, we aimed to study the clinical correlation and biological significance of ESCO1 in bladder cancer. Our results showed that ESCO1 was significantly over-expressed in bladder cancer tissues compared with that in adjacent normal tissues. And, increased ESCO1 expression was significantly associated with higher grade (P < 0.001), higher tumor stage (P = 0.014), and multifocality (P = 0.042). Kaplan–Meier analysis and Cox proportional hazards model were performed to determine the prognostic significance of ESCO1, and the results showed that ESCO1 is a useful prognostic marker for bladder cancer patients. Moreover, we found that ESCO1 knockdown inhibited the growth, migration, and invasion of bladder cancer cells. In conclusion, our findings indicated that ESCO1 may play an important role in human bladder cancer, and ESCO1 might serve as a novel target and prognosis factor for human bladder cancer.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.CrossRefPubMed

Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106(1):57–61. doi:10.1002/jso.23040.CrossRefPubMed

Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9. doi:10.1200/JCO.2004.11.024.CrossRefPubMed

Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177(2):437–43. doi:10.1016/j.juro.2006.09.027.CrossRefPubMed

Zhang J, Shi X, Li Y, Kim BJ, Jia J, Huang Z, et al. Acetylation of Smc3 by Eco1 is required for S phase sister chromatid cohesion in both human and yeast. Mol Cell. 2008;31(1):143–51. doi:10.1016/j.molcel.2008.06.006.CrossRefPubMed

Unal E, Heidinger-Pauli JM, Koshland D. DNA double-strand breaks trigger genome-wide sister-chromatid cohesion through Eco1 (Ctf7). Science. 2007;317(5835):245–8. doi:10.1126/science.1140637.CrossRefPubMed

Barber TD, McManus K, Yuen KW, Reis M, Parmigiani G, Shen D, et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci U S A. 2008;105(9):3443–8. doi:10.1073/pnas.0712384105.CrossRefPubMedPubMedCentral

Price JC, Pollock LM, Rudd ML, Fogoros SK, Mohamed H, Hanigan CL, et al. Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A. PLoS One. 2014;8(6):e63313. doi:10.1371/journal.pone.0063313.CrossRefPubMed

Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, et al. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. Cancer Epidemiol Biomark Prev. 2009;18(11):3030–5. doi:10.1158/1055-9965.EPI-09-0772.CrossRef

10.

Lei Y, Yan S, Ming-De L, Na L, Rui-Fa H. Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem. 2011;113(5):514–8. doi:10.1016/j.acthis.2010.05.004.CrossRefPubMed

11.

Naito S, Bilim V, Yuuki K, Ugolkov A, Motoyama T, Nagaoka A, et al. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res. 2010;16(21):5124–32. doi:10.1158/1078-0432.CCR-10-0275.CrossRefPubMed

12.

Wu CF, Ng KF, Chen CS, Chang PL, Chuang CK, Weng WH, et al. Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract. Br J Cancer. 2010;103(6):852–60. doi:10.1038/sj.bjc.6605835.CrossRefPubMedPubMedCentral

13.

Kwak C, Lee SE, Jeong IG, Ku JH. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology. 2006;68(1):53–7. doi:10.1016/j.urology.2006.01.053.CrossRefPubMed

14.

Mhawech-Fauceglia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer. 2006;106(6):1205–16. doi:10.1002/cncr.21743.CrossRefPubMed

15.

Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 1998;392(6673):300–3. doi:10.1038/32688.CrossRefPubMed

16.

Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, et al. Inactivation of hCDC4 can cause chromosomal instability. Nature. 2004;428(6978):77–81. doi:10.1038/nature02313.CrossRefPubMed

17.

Wang Z, Cummins JM, Shen D, Cahill DP, Jallepalli PV, Wang TL, et al. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res. 2004;64(9):2998–3001.CrossRefPubMed

18.

Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science. 2011;333(6045):1039–43. doi:10.1126/science.1203619.CrossRefPubMedPubMedCentral

19.

Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–78. doi:10.1016/j.cell.2012.06.023.CrossRefPubMedPubMedCentral

20.

Rocquain J, Gelsi-Boyer V, Adelaide J, Murati A, Carbuccia N, Vey N, et al. Alteration of cohesin genes in myeloid diseases. Am J Hematol. 2010;85(9):717–9. doi:10.1002/ajh.21798.CrossRefPubMed

Title: Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer
Authors: Shiying Zhang
Jianye Li
Gaobiao Zhou
Dawei Mu
Jingmin Yan
Jizhang Xing
Zhiyong Yao
Haibo Sheng
Di Li
Chao Lv
Bin Sun
Quan Hong
Heqing Guo
Publication date: 01-04-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4375-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

The dual induction of apoptosis and autophagy by SZC014, a synthetic oleanolic acid derivative, in gastric cancer cells via NF-κB pathway

Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer

Radiosensitisation of human glioma cells by inhibition of β1,6-GlcNAc branched N-glycans

HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)

Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells

Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer